Thejer, Bashar M.
Adhikary, Partho P.
Teakel, Sarah L.
Fang, Johnny
Weston, Paul A.
Gurusinghe, Saliya
Anwer, Ayad G.
Gosnell, Martin
Jazayeri, Jalal A.
Ludescher, Marina
Gray, Lesley-Ann
Pawlak, Michael
Wallace, Robyn H.
Pant, Sameer D.
Wong, Marie
Fischer, Tamas
New, Elizabeth J.
Fehm, Tanja N.
Neubauer, Hans
Goldys, Ewa M.
Quinn, Jane C.
Weston, Leslie A.
Cahill, Michael A.
Funding for this research was provided by:
Charles Sturt University (N/A)
Iraqi Cultural Attaché in Canberra (N/A)
Australian Research Council (CE140100003, DE120102687)
Ramaciotti Foundations (ES2012/0051)
Article History
Received: 18 December 2019
Accepted: 20 March 2020
First Online: 15 April 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: M.A.C. is scientific advisor to and minor shareholder of Cognition Therapeutics, a company developing sigma-2 receptor ligands against Alzheimer’s disease. This work was performed independently of and without input from the company. The authors declare that they have no other competing interests.